PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS RECEIVING 3 TARGETED THERAPIES (TTS) FOR METASTATIC RENAL-CELL CARCINOMA (MRCC)

被引：0
|
作者：
Iacovelli, R. [1 ]
Santoni, M. [2 ]
Di Lorenzo, G. [3 ]
Cerbone, L. [4 ]
Aglietta, M. [5 ]
Masini, C. [6 ]
Giganti, M. O. [7 ]
Messina, C. [8 ]
Sternberg, C. N. [9 ]
Procopio, G. [10 ]
机构：
[1] Univ Roma La Sapienza, Dept Radiol Oncol & Human Pathol, Rome, Italy
[2] Univ Politecn Marche, Ancona, Italy
[3] Univ Federico II, Cattedra Oncol Med, Dept Oncol, Naples, Italy
[4] San Camillo & Forlanini Hosp, Rome, Italy
[5] Fdn Piemontese Ric Cancro Onlus, Div Oncol & Ematol, Candiolo, Italy
[6] Osped Policlin Modena, Dept Hematol Oncol, Modena, Italy
[7] Niguarda Ca Grande Hosp, Milan, Italy
[8] Osped Riuniti Bergamo, I-24100 Bergamo, Italy
[9] San Camillo Forlanini Hosp, Rome, Italy
[10] Ist Nazl Tumori, Fdn IRCCS, I-20133 Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：270 / 271
页数：2
相关论文
共 50 条
  • [21] Progression-Free Survival as a Predictor of Overall Survival in Metastatic Renal Cell Carcinoma Treated With Contemporary Targeted Therapy
    Heng, Daniel Y. C.
    Xie, Wanling
    Bjarnason, Georg A.
    Vaishampayan, Ulka
    Tan, Min-Han
    Knox, Jennifer
    Donskov, Frede
    Wood, Lori
    Kollmannsberger, Christian
    Rini, Brian I.
    Choueiri, Toni K.
    CANCER, 2011, 117 (12) : 2637 - 2642
  • [22] Assessment of Progression-free Survival as a Surrogate Endpoint for Overall Survival in Patients With Metastatic Renal Cell Carcinoma
    Negrier, S.
    Bushmakin, A. G.
    Cappelleri, J. C.
    Charbonneau, C.
    Sandin, R.
    Michaelson, M. D.
    Figlin, R. A.
    Motzer, R. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S163 - S163
  • [23] Factors impacting progression-free survival (PFS) as a predictor of overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John Frederick
    Goss, Glenwood D.
    Fung-Kee-Fung, Michael
    Jonker, Derek J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Targeted therapies (TTs) in metastatic renal cell carcinoma (MRCC): Role of metastatic site as a prognostic and predictive factor
    Procopio, G.
    Grassi, P.
    Porcu, L.
    Verzoni, E.
    Testa, I.
    Garanzini, E.
    Biondani, P.
    Pusceddu, S.
    De Braud, F.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S666 - S666
  • [25] SIMULATION AND COMPARISON OF PROGRESSION-FREE-SURVIVAL OUTCOMES OF SEQUENTIAL TARGETED THERAPY IN METASTATIC RENAL-CELL CARCINOMA
    Mickisch, G. H.
    Schwander, B.
    Cassinello, J. G.
    Carles, J.
    Walzer, S.
    Nuijten, M.
    VALUE IN HEALTH, 2010, 13 (07) : A255 - A255
  • [26] DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic Therapies
    Peters, Inga
    Dubrowinskaja, Natalia
    Abbas, Mahmoud
    Seidel, Christoph
    Kogosov, Michael
    Scherer, Ralph
    Gebauer, Kai
    Merseburger, Axel S.
    Kuczyk, Markus A.
    Gruenwald, Viktor
    Serth, Juergen
    PLOS ONE, 2014, 9 (03):
  • [27] Development of overall survival (OS) and progression free survival (PFS) nomograms for Australian patients with locoregionally advanced oropharyngeal squamous cell carcinoma (LA OPSCC)
    Xu, K.
    Lo, A.
    Chin, V.
    Gzell, C.
    O'Connor, C.
    Forstner, D.
    Gallagher, R.
    Bova, R.
    Crawford, J.
    Harvey, R.
    Lochhead, A.
    Earls, P.
    Qiu, M. R.
    Hsu, E.
    Bigg-Wither, G.
    Chan, L.
    Bao, H.
    Foltyn, P.
    Sim, H-W.
    Prawira, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [28] Conditional survival of patients with metastatic renal-cell carcinoma
    Sun, Maxine
    Quoc-Dien Trinh
    Karakiewicz, Pierre I.
    LANCET ONCOLOGY, 2012, 13 (11): : E462 - E462
  • [29] THE OVERALL SURVIVAL (OS) AND PROGRESSION-FREE SURVIVAL (PFS) OF HYPERPROGRESSIVE DISEASE (HDP) IN LUNG CANCER PATIENTS
    Oh, Youjin
    Djunadi, Trie Arni
    Chung, Liam Il-Young
    Lee, Soowon
    Hong, Timothy
    Shah, Zunairah
    Park, Joo Hee
    Yoon, Sung Mi
    Duan, Richard
    Chae, Young Kwang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1468 - A1469
  • [30] Rethinking Progression-Free Survival (PFS) as a Clinical Trials Surrogate for Overall Survival (OS)
    Stewart, D.
    Bosse, D.
    Ocana, A.
    Goss, G.
    Jonker, D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1782 - S1782
12345